about
Glucocorticoids suppress renal cell carcinoma progression by enhancing Na,K-ATPase beta-1 subunit expressionThird-line sunitinib following sequential use of cytokine therapy and sorafenib in Japanese patients with metastatic renal cell carcinoma.Efficacy and safety of temsirolimus in Japanese patients with metastatic renal cell carcinoma on hemodialysis.Expression of multidrug resistance markers ABCB1 (MDR-1/P-gp) and ABCC1 (MRP-1) in renal cell carcinoma.Induction of cell cycle arrest by increasing GTP‑RhoA levels via Taxol‑induced microtubule polymerization in renal cell carcinoma.VX680/MK-0457, a potent and selective Aurora kinase inhibitor, targets both tumor and endothelial cells in clear cell renal cell carcinoma.Increased Nek1 expression in renal cell carcinoma cells is associated with decreased sensitivity to DNA-damaging treatmentTumour suppressor microRNA-584 directly targets oncogene Rock-1 and decreases invasion ability in human clear cell renal cell carcinomaResidual renal function after partial or radical nephrectomy for renal cell carcinoma.Genetic and epigenetic alterations during renal carcinogenesis.MicroRNA-99a induces G1-phase cell cycle arrest and suppresses tumorigenicity in renal cell carcinomaSystemic adjuvant therapies in renal cell carcinomaFDA drug approval summary: bevacizumab plus interferon for advanced renal cell carcinoma.Characterization of the metabolism of benzaldehyde dimethane sulfonate (NSC 281612, DMS612).Formation of active products of benzaldehyde dimethane sulfonate (NSC 281612, DMS612) in human blood and plasma and their activity against renal cell carcinoma lines.Evaluation of cancer treatment in the abdomen: Trends and advances.MicroRNA-27a functions as a tumor suppressor in renal cell carcinoma by targeting epidermal growth factor receptor.Assessing renal function after partial nephrectomy using renal nuclear scintigraphy and estimated glomerular filtration rateInterleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinomaHistologic variations and immunohistochemical features of metastatic clear cell renal cell carcinoma.Effects of the aldehyde dehydrogenase inhibitor disulfiram on the plasma pharmacokinetics, metabolism, and toxicity of benzaldehyde dimethane sulfonate (NSC281612, DMS612, BEN) in mice.Management of comorbidities in diabetics with renal cell carcinoma: past utilization and current outcomes.Importance of ABCC1 for cancer therapy and prognosis.Long non-coding RNA MEG3 induces renal cell carcinoma cells apoptosis by activating the mitochondrial pathway.Intratracheal and oral administration of SM-276001: a selective TLR7 agonist, leads to antitumor efficacy in primary and metastatic models of cancer.microRNA-155 silencing inhibits proliferation and migration and induces apoptosis by upregulating BACH1 in renal cancer cells.Long-term proliferation of functional human NK cells, with conversion of CD56(dim) NK cells to a CD56 (bright) phenotype, induced by carcinoma cells co-expressing 4-1BBL and IL-12.A thermally targeted peptide inhibitor of symmetrical dimethylation inhibits cancer-cell proliferation.Could the properties of IL-27 make it an ideal adjuvant for anticancer immunotherapy?Health-related quality of life in Japanese patients with metastatic renal cell carcinoma treated with sunitinib.MicroRNA-590-5p regulates cell viability, apoptosis, migration and invasion of renal cell carcinoma cell lines through targeting ARHGAP24.NK-cell dysfunction in human renal carcinoma reveals diacylglycerol kinase as key regulator and target for therapeutic intervention.
P2860
Q28545292-E60B170B-FF2C-4895-948F-11B3DCE1717EQ33398317-220F84B1-DB0C-4E54-BB8D-206CFC2FAEE5Q33404146-C5EA7829-5F01-44B2-958D-D58878A88622Q33474188-01516C23-7E63-43EB-8E28-D9932F580DABQ33702248-5953EF3E-4845-4344-AF4B-3A019704580EQ33942098-7D58671F-4929-4FFE-B154-25A6B760B72DQ34100935-1EC7E1CC-90DB-4B8E-9FA3-0EBCAB20A60AQ34152578-B28F163B-C850-4F78-80F8-4AC3F2ACC049Q34179292-6A1D0546-9860-4828-83D7-A358FE9B0761Q34467232-CC56428C-717A-489B-B287-89C9EAE6FB52Q34485641-F9896DFD-3DF9-402B-A2B9-EA01A8AD4A1AQ35569322-27D7F5A7-7F4C-41BD-976E-815700811AEBQ35583662-FFD0A073-79F6-424E-9FE8-1D3DD756B385Q35984176-564F25F8-05F9-4C5F-A1E4-E45444C03658Q36508219-9D62F36D-340B-4C7C-8716-4928B3FF2584Q36832118-EEA757EA-2DB8-4374-9D0C-C0514B0EBA32Q36954217-97F3ACC5-413F-475A-B864-B9C9A84493B0Q37003658-2319252E-9FA1-4D4F-88AA-F12FAC60C976Q37035437-E6623895-A770-4863-92BF-A3DFA99533BCQ37316716-D9C1CF33-5A43-493C-9F1C-F81148A87A65Q37333224-BA912EF5-803B-4890-BF41-E1A15E2CC12FQ38130645-213C92C2-B5B4-4973-9A23-3093F135EFD5Q38199535-5D21BAF2-A0F8-4FBD-A590-D881658D23B9Q38848043-2F25ECE1-BC94-4584-86FF-EF746DBCBF4AQ39325230-D265CEE2-C7AB-4BE0-A1B3-1FD1286E5911Q39401151-5BB9F422-BD3D-4E7F-B04A-973B0413CF55Q39453997-4AD69F61-7B8C-468A-845F-D84B2E11E927Q39737800-D4B497FC-DADE-4A31-983D-4D09FD833C2EQ41901023-11E81939-0DA7-4939-8C74-B611C0E9A141Q44750309-DC042846-EE92-4558-BBF9-94BD02E444B5Q47667730-E20B2C5F-9F40-4A51-B5AD-7437D13F0D2FQ54369697-080DC4E8-3DA2-4480-8E05-3A643A04E288
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 03 April 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Treatment of metastatic renal cell carcinoma.
@en
Treatment of metastatic renal cell carcinoma.
@nl
type
label
Treatment of metastatic renal cell carcinoma.
@en
Treatment of metastatic renal cell carcinoma.
@nl
prefLabel
Treatment of metastatic renal cell carcinoma.
@en
Treatment of metastatic renal cell carcinoma.
@nl
P1476
Treatment of metastatic renal cell carcinoma.
@en
P2093
Chin Y Liu
David J Reeves
P2888
P356
10.1007/S00280-009-0983-Z
P577
2009-04-03T00:00:00Z